Puretech Presents New Data From Phase 2b Open-Label Extension Study Of Deupirfenidone
Refinitiv1分未満で読めます
PureTech Health PLC 
PRTC:
PURETECH PRESENTS NEW DATA FROM PHASE 2B OPEN-LABEL EXTENSION STUDY OF DEUPIRFENIDONE (LYT-100), FURTHER SUPPORTING STRONG AND DURABLE EFFICACY AND POTENTIAL TO SERVE AS NEW STANDARD OF CARE IN IPF
PURETECH HEALTH PLC - PATIENTS SWITCHING TO DEUPIRFENIDONE ACHIEVED LUNG FUNCTION STABILIZATION WITH FAVORABLE TOLERABILITY
PURETECH HEALTH PLC - PHASE 3 TRIAL DESIGN UPDATE EXPECTED Q4 2025
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう